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Foreword
I welcome the National Advisory Committee on Drugs Report An Overview of New Psychoactive  
Substances and the Outlets Supplying Them as an important contribution to our overall efforts  
to curb the use of such substances.
The issue of new psychoactive substances, and the outlets selling them, are of serious concern to  
societies and to Governments in Ireland and across Europe. Reports such as this highlight the dangers 
involved and set out a comprehensive list of recommendations for addressing the various aspects of  
the problems involved.
A number of initiatives have already been taken in Ireland to tackle the new psychoactive substances 
problem and these have achieved significant success. However, drugs supply and drugs consumption  
tend to shift in response to legislative changes and the report stresses the on-going need for monitoring  
and action to tackle any new risks that emerge with appropriate and timely responses.
I would like to express my appreciation to all those involved in compiling this Report. Among them were  
the research participants who shared their experiences and who contributed valuable insights, the agencies 
that facilitated their participation, the researchers from the School of Chemical and Pharmaceutical Sciences 
at Dublin Institute of Technology; the members of the Research Advisory Group; and Dr Des Corrigan,  
Chair of the NACD, as well as all the staff of the Committee.
Róisín Shortall, T.D. 
Minister for State with Responsibility for Primary Care, Department of Health
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Preface
The NACD has been concerned about the Headshops issue for 
a number of years. In conjunction with the then National Drug 
Strategy Team (NDST) it conducted the first of many briefings for 
Drug Task Forces on the challenges posed by these outlets and 
the New Psychoactive Substances (NPAS) they offered for sale 
through retail and online outlets in December 2007. Intensive 
discussions with the then Minister for Drugs John Curran during 
2009 resulted in a ministerial request to the NACD to prepare a 
report into all aspects of the phenomenon which would inform  
a legislative solution to the problem caused by NPAS.
The NACD convened a multidisciplinary Research Advisory 
Group (RAG) comprised of representatives of An Garda Síochána, 
Customs Drug Law Enforcement, Dept. of Health and Children, 
Office of the Minister for Drugs (Dept. of Community, Equality 
and Gaeltacht Affairs), the Irish Medicines Board, the Food Safety 
Authority of Ireland, The Health and Safety Authority, the Health 
Service Executive, the Forensic Science Laboratory, Citywide Drug Crisis Campaign and the NACD itself.  
The RAG recommended that the NACD commission an in-depth study of the Headshop phenomenon 
including laboratory analysis of the products being offered from both online and retail outlets.
The Request for Tender was issued in February 2010 and the contract for this work was awarded to a  
team from the Centre for Social and Educational Research (CSER) at the Dublin Institute of Technology  
(DIT). The NACD is grateful to Cathy Kelleher, Rachel Christie, Kevin Lalor, John Fox, Matt Bowden and  
Cora O’Donnell of the CSER for their efforts, not least in working to a very tight deadline. The NACD 
also wishes to acknowledge the generosity of Dr Pierce Kavanagh and his colleagues in the Dept. of 
Pharmacology and Therapeutics, Trinity College Dublin who shared their analytical results with the DIT  
team and with the NACD.
The review focuses on potential new substances that may come to be sold in head shops and online 
particularly substances which are not yet controlled under the Misuse of Drugs legislation, and so inform  
a legislative response to deal with such substances. The project includes the chemical analysis of existing 
and novel psychoactive substances, a review of emerging scientific literature, an online survey of users  
and a number of interviews with both ‘recreational’ and ‘problem users’. Risk factors and harm reduction 
measures and approaches to restricting psychoactive substances in other jurisdictions are also considered.
This is an Executive Summary of the report representing the outcome of a review of new psychoactive 
substances1 within the Irish context, including a review of the outlets that supply these substances. The  
full report is available to download from the NACD website www.nacd.ie . Having considered the Report,  
the RAG and the NACD formulated a number of recommendations which were presented to the Minister 
and the Oversight Forum on Drugs (OFD).
1 According to Article 3 of Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances, ‘new psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form or in a preparation that has 
not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, and that may pose a threat to 
public health comparable to the substances listed in Schedule I, II or IV; ‘new psychotropic drug’ means a substance in 
pure form or in a preparation that has not been scheduled under the 1971 United Nations Convention on Psychotropic 
Substances, and that may pose a threat to public health comparable to the substances listed in Schedule I, II, III or IV.
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The NACD recognises the hugely positive effects of the Government decision in May 2010 to schedule  •	
a large number of synthetic cannabinoids and some cathinones (“bath salts”) as Controlled Drugs under 
the Misuse of Drugs Acts and also the subsequent enactment of the Criminal Justice (Psychoactive 
Substances) Act 2010. The NACD recommends that the work of the Department of Health in conjunction 
with the Department of Justice and Law Reform, the Gardaí, the Customs Service, the Forensic Science 
Laboratory, the Irish Medicines Board and others to closely monitor the emergence of new psychoactive 
substances with a view to bringing them under the Misuse of Drugs Act should continue to be supported 
in order to deter efforts to circumvent legislative controls (e.g. the Criminal Justice (Psychoactive 
Substances) Act 2010) on the import of these materials.
Ireland should collaborate more closely with initiatives in the UK and other EU Member States to  •	
restrict access to new psychoactive substances and to ensure that legislative controls are not bypassed.
A challenge may exist in terms of the monitoring of online outlets for the sale and supply of new •	
psychoactive substances. In terms of further addressing the issue, efforts could be made to examine 
existing models of online monitoring which may curtail such trade including, for example, the model  
of co-operation in place between the Irish Medicines Board and the Customs authorities to monitor  
the sale of counterfeit medicines.
The Report includes evidence that many products containing new psychoactive substances are placed •	
on the market as food. These foods also contain drugs such as caffeine, synephrine, 2-PEA and DMAA 
or else substances which are naturally found in foodstuffs. Consumer protection in respect of such foods 
should be a matter for the Food Safety Authority of Ireland in the context of food legislation.
Preliminary contacts indicate that there is no readily accessible national database on the health-related •	
issues experienced by individuals who have consumed new psychoactive substances presenting to 
Emergency Departments of Acute Hospitals. The development of a centralised national database to 
collect data from Emergency Departments on alcohol and other drug use, as well as presenting issues 
and demographic data, which could be developed and managed by an appropriate agency, such as the 
Health Research Board or the Economic and Social Research Institute (which details hospital admissions 
each year) is recommended. This would make it possible to verify the harm being caused by existing  
and newly emerging drugs. Standardisation of information collected by Emergency Departments will  
be key to implementing this recommendation. This has implications in relation to further data collection 
in relation to alcohol and other drugs in Emergency Departments.
The National Drugs Awareness Campaign recently launched by the HSE to raise awareness of the •	
dangers and significant mental and physical health effects that can be caused by psychoactive substances 
should take account of user experiences of new psychoactive substances as recorded in the project Report.
Online awareness campaigns, along the lines developed by Drugs.ie which use advertisements on •	
Facebook and Twitter, as well as active engagement with online discussion sites and other online media 
outlets frequented by young people, play an important role in highlighting the risks of psychoactive 
substances. In addition to the potential health risks posed by psychoactive substances, users run the risk 
of unintentionally engaging in criminal behaviour through the purchase of so called ‘legal’ psychoactive 
substances that in fact contain controlled substances. The National Drugs Awareness Campaign could 
communicate this issue to users who may otherwise not be aware of the facts and the risks involved.
Section 5 of the Report highlights the importance of accurate and context-specific harm reduction •	
messages in the early days of emergent drug use, when both scientific and lay knowledge is limited. 
Given the level of polydrug use reported by survey respondents, it is recommended that harm reduction 
interventions are designed to target this pattern of substance abuse. Targeted harm reduction messages 
and guidelines for stimulant use aimed at problematic drug users along the lines developed by the  
Key Findings
A
n
 E
xe
cu
tive
 S
u
m
m
ary o
f an
 O
ve
rvie
w
 o
f N
e
w
 P
sych
o
active
 S
u
b
stan
ce
s an
d
 th
e
 O
u
tle
ts S
u
p
p
lyin
g
 T
h
e
m
N
A
C
D
 2
0
1
1
7
Ana Liffey Drugs Project are also recommended and should inform public health promotion campaigns. 
This could be facilitated through better signposting of harm reduction advice on the Drugs.ie website.
It is recommended that the impact of recent legislative changes is assessed, so that any new risks that •	
may emerge can be identified and appropriate responses made. In this context, it is recommended  
that research on emerging trends in drug use should be seen as a priority for the social and biomedical 
science research communities and their funding bodies.
A standardised system of recording and reporting intoxications would enhance the potential to •	
understand and respond to risks associated with new psychoactive substances. In order to facilitate 
this, there is a need to have rapid access to a suitably equipped laboratory that can take on the task 
of rigorous testing of new and emerging psychoactive substances, a laboratory that has the time and 
manpower to test identity, purity and concentration. Such a laboratory would provide timely information  
in relation to the detection of new psychoactive substances which would facilitate the early dissemination 
of harm reduction messages.
For the purposes of identification of new psychoactive substances by forensic and pathology •	
laboratories, and the development of drug field tests, there is an urgent need to establish a body 
providing a catalogue of reference standards speedily and at affordable prices. Such a body could 
provide a dedicated service not just to Ireland but to other EU countries, thus providing a continent-wide 
service/resource to address the issue of newly emerging psychoactive substances. In the context of the 
forthcoming review of the Council Decision on information, exchange, risk assessment and control of  
new psychoactive substances, this needs to be raised by Ireland at EU fora such as the Horizontal  
Drugs Group.
The British government announced on August 20, 2010, that it will introduce legislation in the first session •	
of parliament to temporarily ban psychoactive substances that are currently legal, but used by people to 
become intoxicated. The temporary ban will mean that it will be unlawful to possess with intent to supply, 
offer to supply, import, export, or produce the drugs in question under the UK Misuse of Drugs Act 1971. 
The introduction of legislation in Ireland that would allow temporary control of psychoactive substances 
pending assessment of the risks of the constituents is also recommended. This would prevent adverse 
health events.
I want to take this opportunity to thank the members of the RAG :- Ms Marita Kinsella, Dr. Jean Long,  
Dr. Brian Redahan, Mr. Raymond Ellard, Dr JM Morris, Dr. Audrey O’Donnell, Dr Carol Downey, Ms Dairearca 
Ní Néill, Ms Maria Ryan, Ms Gillian Treacy, Ms Majella Cosgrave, Ms Sinead O’Mahony Carey, Mr. John Garry, 
Mr Niall Cullen, Mr. Daithi Doolan, Detective Sgt. Brian Roberts, Mr. Tony Duffin, for their commitment and 
for so readily sharing their individual and corporate expertise.
As ever my colleagues and I are indebted to Ms Susan Scally the then interim Director of the NACD and  
her colleagues, Alan Gaffney and Mary Jane Trimble for their efforts in preparing this Report for publication.
While many Headshops have closed and a large number of products are no longer on open sale it is well 
known that some are still available either on the black market or over the internet. These chemicals pose 
ongoing challenges but thanks to this Report we have a clearer picture of exactly what those challenges are.
Dr Des Corrigan FPSI 
Chairperson NACD
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Background to research
Head shop retail outlets supplying non-regulated substances have recently come to public attention in 
Ireland, thereby sparking considerable media and political debate about the potentially hazardous effects 
of these substances. Their widespread availability is also of concern to governments across Europe and 
elsewhere, due to the unpredictable side effects and lack of quality control of such substances. In addition, 
the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) has recently highlighted the 
need to step up national-level data collection on such substances, particularly those containing cathinones 
and synthetic cannabinoids. The substances come from unregulated sources, and are frequently described 
as ‘research chemicals’ which have no medicinal application.
The recreational use of new psychoactive substances has been increasing in parallel with developments such 
as greater economic globalisation and freer, de-regulated supply chains. Both non-regulated substances and 
controlled substances are a source of insecurity and uncertainty in the face of Ireland’s exposure to global 
supply chains. Moreover, both types of substances pose potential risks to users, as evidenced by the volume 
of anecdotal accounts of negative side effects following consumption of these substances. Head shops tend 
to be located in busy areas of cities and towns, and particularly in areas associated with the leisure industry 
and the night-time economy.
It appears that certain groups of users, most notably current problem drug users, are especially at risk. In 
addition, there is concern about the wider public health issue and the social risks associated with problem 
drug use. For these reasons, national-level action is required to improve existing knowledge and thus enable 
appropriate public policy and timely interventions. The authors of this document are endeavouring to make 
a significant contribution in this respect.
The review aims to provide an overview of new psychoactive substances in Ireland, which were not at the 
time subject to national legal controls, and to review the outlets supplying these substances. The review 
was undertaken by a research team at Dublin Institute of Technology (DIT) who mobilised expertise from 
both the scientific field and the social sciences field. The scientific input was provided by personnel from the 
School of Chemical and Pharmaceutical Sciences, and the social scientific input was provided by researchers 
at the Centre for Social and Educational Research (CSER), which operates under the aegis of the School of 
Social Sciences and Law.
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Introduction
This is an Executive Summary of the report representing the outcome of a review of new psychoactive 
substances2 within the Irish context, including a review of the outlets that supply these substances.  
The full report is available to download from the NACD website www.nacd.ie.
The review was commissioned by the National Advisory Committee on Drugs (NACD) in accordance with 
Action 14 of the National Drugs Strategy (interim) 2009-2016. Action 14 provides for the monitoring of ‘head 
shops’3 and other outlets for the sale of psychoactive substances, under the Misuse of Drugs Act 1977 and the 
Misuse of Drugs (Amendment) Regulations 2007. Researchers at the Centre for Social and Educational Research 
(CSER) within the School of Social Sciences and Law at Dublin Institute of Technology (DIT), and at the School 
of Chemical and Pharmaceutical Sciences (DIT), conducted the review between May and August 2010.
The proliferation of head shops and online retailers has facilitated the emergence of a range of new 
psychoactive substances in Ireland. Such outlets have supplied products containing powerful synthetic 
substances that mimic the common illegal stimulants cocaine, ecstasy and amphetamine; they have also 
supplied synthetic cannabinoids designed to serve as cannabis substitutes. Often these substances are 
‘research chemicals’, with no medicinal value, and where there is little existing knowledge in relation to their 
safety or toxicity. The location of head shops in prominent areas has highlighted their existence, and has 
fuelled concerns relating to their unknown potential for causing harm. The ‘head shop phenomenon’ has 
received unprecedented attention from the general public and the media, while the dynamic nature of the 
phenomenon has led to demands for a swift and comprehensive response from legislators.
In response to the ‘phenomenon’, the Government introduced legal measures, including the control of BZP 
(March 2009) and the control of mephedrone (May 2010). Also in May 2010, the Government made an Order 
under the Misuse of Drugs Acts 1977 and 1984 controlling a broad range of new psychoactive substances, including 
benzylpiperazine derivatives, synthetic cannabinoids and a number of named cathinones. In August 2010, the 
Criminal Justice (Psychoactive Substances) Act 2010 came into operation, making it an offence to sell, import, 
export or advertise psychoactive substances. This move coincided with a sharp decrease in the number of 
head shops which had been open for business and a significant decrease in the availability of new 
psychoactive substances in the few shops remaining open.
This review represents the aggregation of available knowledge on new psychoactive substances within 
the Irish context, and empirical research aimed at providing new insights into this complex phenomenon. 
Specifically, the review sought to assess the availability and accessibility of new psychoactive substances in 
retail outlets throughout Ireland and online, and to identify and describe the products, and where possible, 
their specific contents. A range of new psychoactive substances was acquired and was subjected to Gas 
Chromatography Mass Spectrometry (GC-MS) chemical analysis in order to identify active constituents.  
The availability of reference standards for the analysis of new psychoactive substances was also determined.
2 According to Article 3 of Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances, ‘new psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form or in a preparation that has 
not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, and that may pose a threat to 
public health comparable to the substances listed in Schedule I, II or IV; ‘new psychotropic drug’ means a substance in 
pure form or in a preparation that has not been scheduled under the 1971 United Nations Convention on Psychotropic 
Substances, and that may pose a threat to public health comparable to the substances listed in Schedule I, II, III or IV.
3 ‘Head shops’ are retail outlets specialising in the sale of new psychoactive substances and/or drug paraphernalia  
(e.g. pipes and bongs).
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Alongside the analyses, published data in relation to new psychoactive substances and their effects were 
reviewed and an online survey of users of head shop products or ‘legal highs’ (as they are commonly known) 
was conducted in order to gain insights into patterns of use and reported effects. To further explore the use 
and effects of these substances, semi-structured interviews were conducted with both ‘recreational’ users 
and ‘problem’ drug users. Based on available information and data gathered, a number of risks associated 
with the use of new psychoactive substances were identified. Harm-reduction measures to minimise risk to 
users were considered in light of existing advice for users of cannabis and stimulant drugs. Finally, measures 
taken in other jurisdictions to restrict psychoactive substances were examined.
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Key findings of the review are summarised below:
Chemical analyses
A total of 42 post-Ban products and seven pre-Ban products were sourced from Irish head shops and online 
outlets. These products were analysed using either Gas Chromatography Mass Spectrometry (GC-MS) or the 
TICTAC database, where applicable. All products were in powder and tablet form, with the exception of just 
one – a herbal smoking product.
The analyses revealed the following:
Caffeine was present in 26 of the 42 products (61%).•	
The following new psychoactive substances, which did not come under the Government Orders, were •	
detected during the analysis: dimethylcathinone, naphyrone, fluorotropacocaine, desoxypipradrol and 
dimethylamylamine. Naphyrone was the most frequently observed of the new psychoactive substances, 
being identified in 12% of samples.
Of all types of new psychoactive substances, the packaging of those in powder form listed the least •	
amount of information: 79% of powder products listed no ingredients. In contrast, 75% of tablet products 
and 67% of capsule products listed ingredients. None of the herbal products listed ingredients.
The most frequently listed ingredients on packaging were •	 Citrus aurantium, anhydrous caffeine, 
Pelargonium graveolens and Theobroma coca.
Controlled substances were found in two of the 37 products sourced in Irish head shops. The controlled •	
substance detected in these two products was 3,4-Methylenedioxypyrovalerone (MDPV).
When tested, all of the products purchased prior to the Government Order (May 2010) contained •	
substances that came under control with the Order. Mephedrone was the most frequent psychoactive 
substance encountered in the analysis of these products (67%).
Five products purchased online underwent analysis and all five contained controlled substances. The •	
controlled substances detected were MDPV, mephedrone and 1-(3-Trifluoromethylphenyl) piperazine 
(TFMPP).
Availability of new psychoactive substances
The number of head shops in Ireland has been decreasing significantly on foot of actions taken by the •	
Government to restrict and control new psychoactive substances.
The number of online retailers is vast. Many of these retailers appear to deliver to Ireland.•	
At the time of the review, fewer people appeared to be purchasing new psychoactive substances via the •	
Internet relative to their UK counterparts.
The use and effects of new psychoactive substances
Very little data has been published on the recreational use of, or the effects of, new psychoactive substances. 
Some pharmacological data has been published on substances which have been used for research purposes 
or for medicinal purposes. In the absence of scientific evidence, it is advisable to consider each new 
substance as unique in its action and in its effects, and to exercise caution with respect to inferring effects 
of substances based on structure-activity relationships. Subjective user reports are plentiful, but must be 
interpreted with caution. The current investigation revealed the following key findings:
Summary of key findings
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Problem drug users appear to be an especially vulnerable subgroup of new psychoactive substance •	
users. Frequently, substances were being used in large quantities, and were also being used 
intravenously. The pattern of use is associated with increased health and social risks to the individual, and 
is also associated with public health risks. In particular, the use of new psychoactive substances among 
problem drug users has been associated with skin and vein damage, increased occurrence of abscesses 
and ulcers, and the rapid onset of psychosis.
The use of new psychoactive substances among problem drug users appeared to have led to a change •	
in the pattern of heroin use, which did not involve a reduction. Instead, heroin and new psychoactive 
substances were being used either simultaneously or successively to stave off or cope with the negative 
‘come-down’ effects experienced with each substance.
‘Amplifier’ or ‘Amplified’, a product which has been shown to contain dimethocaine (Kavanagh •	 et al., 
2010c)4, may be especially potent when used intravenously in high doses.
Problem drug users’ reports of compulsive re-dosing and tolerance effects may be indicative of the abuse •	
potential of new psychoactive substances in powder form.
Survey findings indicated a pattern of recent infrequent use of new psychoactive substances among a •	
subgroup who may be described as ‘recreational’ users of new psychoactive substances. It is likely that 
this pattern of usage reflects the impact of the May 2010 Government ban on a range of substances. 
The use of substances available before the May 2010 Order was reported more often than the use of 
substances available after the May 2010 Order.
A wide range of new psychoactive substances had been sampled by survey respondents. The use •	
of mephedrone and BZP was most widely reported. The use of ethnobotanical substances was less 
common; however Salvia divinorum was sampled by almost a quarter of all survey respondents.
Users of new psychoactive substances tended to have a history of illegal drug use (notably cannabis, •	
ecstasy, and cocaine) and use of new psychoactive substances was related in particular to two factors: 
‘curiosity’ and ‘availability’. Following the introduction of controls on a range of new psychoactive 
substances (May 2010), and in anticipation of further restrictions on such substances being introduced , 
it appears that users may be switching back to illegal drugs such as cannabis, ecstasy and cocaine. The 
authors of this report recommend that the impact of legislative changes on the pattern and use of new 
psychoactive substances be monitored closely.
‘Recreational’ users of new psychoactive substances are likely to mix them with other substances, •	
especially cannabis, ecstasy and cocaine.
Among ‘recreational’ users, reported subjective negative effects were more frequently associated with •	
new psychoactive substances in powder form than with such substances in tablet form. Powders were 
associated with memory loss/blackouts in particular. Palpitations were associated with both powder-form 
and tablet-form substances, and these palpitations seem to have been especially worrying for some 
users.
4 Kavanagh PV, McNamara S, Angelov D, Mc Dermott S, Mullan D and Ryder S (2010c) Head shop ‘legal highs’ active 
constituents identification chart (June 2010, post ban). Department of Pharmacology and Therapeutics, School of 
Medicine, Trinity Centre for Health Sciences, St James’s Hospital, Dublin 8; Drug Treatment Centre Board, Pearse Street, 
Dublin 2; School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2.
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It appears that some individuals expect negative effects from new psychoactive substance use, while •	
others do not. Almost 40% of those reporting memory loss/blackouts in the current study said they 
anticipated this effect. It is possible that the unexpected nature of various negative effects may have 
contributed to the discomfort or distress experienced by some users. While two interviewees reported 
surprising and distressing effects after taking Salvia divinorum for the first time, they reported more 
favourable experiences after taking it on subsequent occasions.
Although ‘recreational’ users of new psychoactive substances experienced negative effects, they did not •	
appear to be seeking medical or psychological help as a result.
Only three survey respondents (1.5%) had accessed emergency medical services as a result of the use of •	
new psychoactive substances.
The extent to which recreational users engage in behaviours intended to minimise harm related to the •	
use of new psychoactive substances is unclear, but it is likely that such behaviours may be more common 
among more experienced drug takers.
Risk factors associated with the use of new psychoactive substances
The following points are highlighted in the context of considering the potential risks associated with the use 
of new psychoactive substances:
Users of new psychoactive substances may inadvertently engage in criminal behaviour if they purchase •	
a supposedly legal substance which actually contains a controlled substance. This may especially be the 
case with online purchases, which may contain controlled substances, despite purporting otherwise.
The lack of consistency between the advertised content and the actual content of some new psychoactive •	
substance products may increase the likelihood of misuse and overdose. In addition, a lack of consistency 
in the active content of individual products over time may put users at risk of misusing the substance, or 
of overdosing.
The combination of substances contained in individual products creates a potential risk of problematic •	
drug interactions.
There is little information available on the safety or toxicity of new psychoactive substances. In addition, •	
guidelines on dosage are unclear, thus potentially increasing the likelihood of overdose.
The lack of knowledge about the toxicity and effects of new psychoactive substances may mean that •	
harm-reduction options are not always clear.
The lack of information regarding new psychoactive substances makes it difficult to suggest specific •	
harm-reduction advice to users. In the absence of the requisite knowledge, harm-reduction advice 
relating to the use of stimulants and cannabis may be appropriate.
The absence of reference standards for new psychoactive substances means that toxicological analysis •	
can be difficult.
The abuse potential of many new psychoactive substances is as yet unknown.•	
Legal responses
The Criminal Justice (Psychoactive Substances) Act 2010 is unique in its approach to addressing the issue •	
of new psychoactive substances. Its introduction has coincided with a sharp reduction in the number of 
head shops in Ireland.
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1. A challenge may exist in relation to the monitoring of online outlets for the sale and supply of new 
psychoactive substances. In terms of further addressing the issue, efforts could be made to examine 
existing models of online monitoring which may curtail such trade, including, for example, the model  
of co-operation in place between the Irish Medicines Board and the Customs authorities to monitor  
the sale of counterfeit medicines.
2. Given Ireland’s close proximity to/cultural links with the UK, it should collaborate more closely with UK 
initiatives, and it should also collaborate with other EU countries to put in place measures to restrict 
access to new psychoactive substances.
3. The ‘Hospital Emergency Departments’ component of this study is as yet incomplete. However, 
preliminary contacts indicate that there is no readily accessible database of ‘presenting issues’ in  
relation to hospital emergency departments. The lack of such information makes it impossible to 
quantify the harm being caused by existing and newly emerging synthetic chemicals. It is recommended 
that any relevant information collected at local hospital level be stored centrally in an appropriate 
agency such as the Health Research Board (HRB); the Economic and Social Research Institute (ESRI), 
which details hospital admissions each year; or in the National Advisory Committee on Drugs (NACD). 
The implementation of such a measure would result in creating a clearer, empirical picture of the harm 
being caused by head shop products and it would replace the current practice of relying on anecdotal 
reports.
4. A system of routine reporting of new psychoactive substances intoxication to the National Poisons 
Information Centre is recommended, in order to facilitate the building of a knowledge base.
5. The survey results show that many users report strong negative reactions following ingestion of ‘legal 
highs’; the results also indicate the existence of a vibrant online community of (mostly) young people 
who are willing to experiment with and discuss new psychoactive substances. In contrast, the public 
health message about the risks/dangers of ‘legal highs’ is rather muted, particularly in the online fora 
frequented by young people. The authors of this report recommend a much more dynamic stating of 
the risks of ‘legal highs’ on the various online media outlets used by young people; this would include 
advertising on Facebook, actively engaging with threads in chat rooms and so on.
6. Given the level of polydrug use reported by survey respondents, it is recommended that interventions 
be designed to specifically target this pattern of substance abuse.
7. Initial indications are that drug consumption choices and patterns of use are shifting in response 
to recent legislative changes. It is recommended that the impact of these changes be monitored 
and assessed, so that any new risks that may emerge can be identified, and appropriate responses 
developed.
8. Ireland does not have a specific research laboratory dedicated to the monitoring of developments 
in new psychoactive substances. The potential exists for the establishment of a dedicated laboratory 
where rigorous testing of new and emerging psychoactive substances  could be carried out – a laboratory 
which has sufficient time and manpower resources to regularly test for features such as purity and 
concentration in any new product that appears on the market.
Conclusions and recommendations
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9. The availability of reference standards for new psychoactive substances is limited. The companies 
providing these standards charge premium rates, possibly due to lack of competition in this area. In 
addition, the time frame required in order to procure reference standards can be prohibitive. In some 
cases, a licence must be obtained for the particular substance before a reference standard can be 
ordered; delivery time thereafter may take a number of weeks. There is scope for the establishment in 
Ireland of a reference standards body/company which could respond rapidly as new substances appear 
on the market. This reference standards body could provide a dedicated service not just to Ireland but 
to other EU countries, thus providing a continent-wide service/resource to address the issue of newly 
emerging psychoactive substances.
10. The continuation of a pragmatic public health approach to new psychoactive substances is 
recommended. Despite historical efforts to control a variety of substances, these substances have 
consistently been available through illegal suppliers. In keeping with the public health approach, a 
number of broad harm-reduction measures are suggested; these are outlined in section 4.2 of the full 
report.
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